The Complement Factor I pipeline drugs market research report outlays comprehensive information on the Complement Factor I targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Complement Factor I pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology which include the indications Geographic Atrophy, and Dry (Atrophic) Macular Degeneration. It also reviews key players involved in Complement Factor I targeted therapeutics development with respective active and dormant or discontinued products.
The Complement Factor I pipeline targets constitutes close to two molecules. Out of which, approximately two molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in and Preclinical stages are and 2 respectively.
Complement Factor I overview
Complement Factor I is a pivotal player in the intricate network of the complement system, an essential component of the immune system. Functioning as a serine protease, this enzyme plays a crucial role in maintaining the delicate balance of the complement cascade. Its primary responsibility lies in the regulation of complement activation by selectively cleaving and inactivating specific complement proteins, namely C3b and C4b. One of the notable aspects of Complement Factor I is its role as a cofactor for Factor H, working collaboratively to orchestrate the degradation of C3b and C4b. The implications of Complement Factor I extend to various diseases, particularly autoimmune disorders and kidney diseases. When Factor I is either mutated or deficient, the result can be uncontrolled complement activation and subsequent tissue damage.
For a complete picture of Complement Factor I’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
